Sebela Pharmaceuticals, Inc.

 Company Summary:
  • Sebela Pharmaceuticals, Inc. (“Sebela”) is a privately held, US-focused commercialization and development organization that markets pharmaceuticals across three therapeutic franchises; Gastroenterology, Women’s Health, and Dermatology.  Sebela's strategy is to leverage its 110 member internal sales force by acquiring sub-optimally marketed products, commercializing new products and driving increased penetration of existing products.  
Transaction Overview:
  • 1 May, 2018:  Metalmark completed a minority investment in Sebela (via a convertible preferred equity security), combining with debt financing and equity from existing Sebela shareholders to finance the acquisition of Braintree.
  • Braintree Laboratories, Inc. ("Braintree"), a privately held, fully integrated specialty pharmaceutical company. In addition to being a market leader in the colonoscopy preparation market, Braintree also has an attractive portfolio of products in the FDA approval pipeline.
Significance of the Transaction:
  • The acquisition of Braintree presents considerable strategic fit with Sebela's focus in Gastroenterology, while the combination of the two companies is expected to generate meaningful synergies.
Healthios Role:
  • Healthios served as strategic adviser to Metalmark Capital on its investment in Sebela
  • This transaction demonstrates Healthios’ deep domain expertise and access to unique growth strategies which generate superior investment return.